Lebrikizumab Improves Hand and Face Dermatitis in Most Patients at 16 Weeks

Analysis of phase 3 trial data show about two-thirds of patients with atopic dermatitis who responded to the IL-13 inhibitor also saw benefit for difficult-to-treat hand and face eczema.

Related Keywords

Washington , United States , Jennye Murase , , University Of California San Francisco , Revolutionizing Atopic Dermatitis , California San Francisco , Eli Lilly Funded ,